Christopher Peetz Sells 7,098 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,098 shares of the company’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total value of $662,456.34. Following the completion of the transaction, the chief executive officer directly owned 163,733 shares in the company, valued at $15,281,200.89. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mirum Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:MIRM traded down $1.74 on Friday, hitting $94.29. 802,708 shares of the company’s stock were exchanged, compared to its average volume of 890,067. The stock has a market capitalization of $4.85 billion, a price-to-earnings ratio of -109.64 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $96.84. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The business’s 50 day simple moving average is $76.87 and its two-hundred day simple moving average is $70.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm’s revenue was up 47.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.30) EPS. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. MCF Advisors LLC lifted its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000. Comerica Bank raised its stake in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares in the last quarter. Quarry LP bought a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $41,000. Finally, CWM LLC lifted its position in Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MIRM. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Leerink Partners set a $100.00 price target on Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Raymond James Financial restated a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. HC Wainwright restated a “buy” rating and issued a $102.00 price objective (up from $81.00) on shares of Mirum Pharmaceuticals in a report on Tuesday, January 13th. Finally, Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.58.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.